Compare Cytokinetics Inc (CYTK) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Alliant Energy Corporation — how do they compare? Cytokinetics Inc trades at $76.41 (market cap $10.63B), while Alliant Energy Corporation trades at $70.01 (market cap $17.78B). The key difference: Alliant Energy Corporation is the larger of the two by market cap, and Alliant Energy Corporation pays a 3.12% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | LNT | |
|---|---|---|
Market Cap | $10.63B | $17.78B |
Sector | Technology | Utilities |
52-Week High | $87.26 | $78.03 |
52-Week Low | $34.31 | $63.62 |
Enterprise Value | $10.74B | $29.88B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Alliant Energy (LNT) trades at $68.21, down 1.67% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.65, beating estimates, and reaffirmed full-year guidance. Revenue grew to $4.36B in 2025, with net income margin at 18.45%. Analyst consensus is a Buy with a $77.67 price target, indicating potential upside. Recent news highlights institutional activity, including Assenagon Asset Management increasing its stake by 339.9% as of August 12, 2026.
LNT presents a stable investment opportunity with consistent earnings beats and a dividend yield, but faces risks from rising debt levels and bearish technical trends. The stock's valuation metrics, including a P/E of 21.7, are reasonable for the utilities sector. Upside is supported by analyst targets, while headwinds include higher interest costs and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
